pHEMA-nHA encapsulation and delivery of vancomycin and rhBMP-2 enhances its role as a bone graft substitute

Clin Orthop Relat Res. 2013 Aug;471(8):2540-7. doi: 10.1007/s11999-012-2644-5.

Abstract

Background: Bone grafts are widely used in orthopaedic procedures. Autografts are limited by donor site morbidity while allografts are known for considerable infection and failure rates. A synthetic composite bone graft substitute poly(2-hydroxyethyl methacrylate)-nanocrystalline hydroxyapatite (pHEMA-nHA) was previously developed to stably press-fit in and functionally repair critical-sized rat femoral segmental defects when it was preabsorbed with a single low dose of 300 ng recombinant human bone morphogenetic protein-2/7 (rhBMP-2/7).

Questions/purposes: To facilitate clinical translation of pHEMA-nHA as a synthetic structural bone graft substitute, we examined its ability to encapsulate and release rhBMP-2 and the antibiotic vancomycin.

Methods: We analyzed the compressive behavior and microstructure of pHEMA-nHA as a function of vancomycin incorporation doses using a dynamic mechanical analyzer and a scanning electron microscope. In vitro release of vancomycin was monitored by ultraviolet-visible spectroscopy. Release of rhBMP-2 from pHEMA-nHA-vancomycin was determined by ELISA. Bioactivity of the released vancomycin and rhBMP-2 was examined by bacterial inhibition and osteogenic transdifferentiation capabilities in cell culture, respectively.

Results: Up to 4.8 wt% of vancomycin was incorporated into pHEMA-nHA without compromising its structural integrity and compressive modulus. Encapsulated vancomycin was released in a dose-dependent and sustained manner in phosphate-buffered saline over 2 weeks, and the released vancomycin inhibited Escherichia coli culture. The pHEMA-nHA-vancomycin composite released preabsorbed rhBMP-2 in a sustained manner over 8 days and locally induced osteogenic transdifferentiation of C2C12 cells in culture.

Conclusions: pHEMA-nHA can encapsulate and deliver vancomycin and rhBMP-2 in a sustained and localized manner with reduced loading doses.

Clinical relevance: The elasticity, osteoconductivity, and rhBMP-2/vancomycin delivery characteristics of pHEMA-nHA may benefit orthopaedic reconstructions or fusions with enhanced safety and efficiency and reduced infection risk.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / chemistry
  • Bone Morphogenetic Protein 2 / administration & dosage*
  • Bone Morphogenetic Protein 2 / chemistry
  • Bone Substitutes / chemistry*
  • Cell Line
  • Cell Transdifferentiation / drug effects
  • Chemistry, Pharmaceutical
  • Coated Materials, Biocompatible*
  • Compressive Strength
  • Delayed-Action Preparations
  • Drug Carriers*
  • Drug Compounding
  • Elasticity
  • Escherichia coli / drug effects
  • Escherichia coli / growth & development
  • Humans
  • Hydroxyapatites / chemistry*
  • Mice
  • Microscopy, Electron, Scanning
  • Osteogenesis / drug effects
  • Polymethacrylic Acids / chemistry*
  • Recombinant Proteins / administration & dosage
  • Solubility
  • Spectrophotometry, Ultraviolet
  • Surface Properties
  • Time Factors
  • Vancomycin / administration & dosage*
  • Vancomycin / chemistry

Substances

  • Anti-Bacterial Agents
  • BMP2 protein, human
  • Bone Morphogenetic Protein 2
  • Bone Substitutes
  • Coated Materials, Biocompatible
  • Delayed-Action Preparations
  • Drug Carriers
  • Hydroxyapatites
  • Polymethacrylic Acids
  • Recombinant Proteins
  • poly(2-hydroxyethyl methacrylate)-nanocrystalline hydroxyapatite
  • Vancomycin